Guro Løvik Goll

Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial

Kristin Kaasen Jørgensen, Inge Christoffer Olsen, Guro Løvik Goll et al. · The Lancet · 2017 · 806 citations

Pharmacy, Internal Medicine, Pharmacotherapy +11

High anti-cyclic citrullinated peptide levels and an algorithm of four variables predict radiographic progression in patients with rheumatoid arthritis: results from a 10-year longitudinal study

Silje Watterdal Syversen, Per Ivar Gaarder, Guro Løvik Goll et al. · Annals of the Rheumatic Diseases · 2007 · 315 citations

Life Sciences, Immunology, Autoimmunity +15

Effect of Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy on Disease Control in Patients With Immune-Mediated Inflammatory Diseases

Silje Watterdal Syversen, Kristin Kaasen Jørgensen, Guro Løvik Goll et al. · JAMA · 2021 · 160 citations · Full text

Medicine, Immunology, Pharmacotherapy +16

Prediction of radiographic progression in rheumatoid arthritis and the role of antibodies against mutated citrullinated vimentin: results from a 10-year prospective study

Silje Watterdal Syversen, Guro Løvik Goll, Désirée van der Heijde et al. · Annals of the Rheumatic Diseases · 2009 · 139 citations

Life Sciences, Immunology, Internal Medicine +17

Long‐term efficacy and safety of biosimilar infliximab (CT‐P13) after switching from originator infliximab: open‐label extension of the NOR‐SWITCH trial

Guro Løvik Goll, Kristin Kaasen Jørgensen, J. Sexton et al. · Journal of Internal Medicine · 2019 · 122 citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +13